Recent advances in the treatment of pancreatic cancer

Abstract

F1000 Faculty Reviews are written by members of the prestigious . They are F1000 Faculty commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. AbstractPancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12): 1200-10. PubMed Abstract | Publisher Full Text 4. Oettle H, Neuhaus P, Hochhaus A, et al.: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14): 1473-81. PubMed Abstract | Publisher Full Text 5. Neoptolemos JP, Palmer DH, Ghaneh P, et al.: Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073): 1011-24. PubMed Abstract | Publisher Full Text | F1000 Recommendation 6. Conroy T, Hammel P, Hebbar M, et al.: FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25): 2395-406. PubMed Abstract | Publisher Full Text | F1000 Recommendation 7. Tempero MA, Reni M, Riess H, et al.: APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. JCO. 2019; 37: 4000. Publisher Full Text 8. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817-25. PubMed Abstract | Publisher Full Text | F1000 Recommendation 9. Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691-703. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 10. Wang-Gillam A, Li CP, Bodoky G, et al.: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (N...

Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β

“…It remains a challenging disease due to its aggressive nature, late clinical presentation, early metastasis to local and distant organs, and inherent resistance to current therapies [5,6]. The standard management relies on cytotoxic chemotherapy, primarily fluorinated pyrimidine antimetabolites (gemcitabine, fluorouracil), topoisomerase I inhibitor (irinotecan), DNA crosslinking agents (oxaliplatin, cisplatin), tubulin inhibitors (paclitaxel, nab-paclitaxel) as well as other regimens [7][8][9]. However, these therapeutic options showed limited therapeutic response and outcome in a subset of PC patients and often resulted in high toxicity [8].…”

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

“…As the results of preclinical and clinical studies discussed above and presented in summary tables suggest, the application of monoclonal antibody-based agents in the treatment of pancreatic cancer is more likely to be successful when used in combination with other therapies such as cytotoxic drugs, other mAbs, cancer vaccines and/or oncolytic viruses. In addition, simultaneous targeting of signalling pathways, the tumour stroma and the incorporation of immune checkpoint inhibitors could yield better results by modifying the immunosuppressive environment of pancreatic tumours [ 70 , 177 , 178 , 179 , 180 , 181 ].…”

Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management

“…The trial comparing extracellular matrix degrader pegvorhyaluronidase alfa (PEGPH20) was stopped as its primary end-point was not met[ 200 ]. The results of the clinical trial AVENGER 50 comparing modified FOLFIRINOX with or without CPI-613 are awaited[ 201 ].…”